Warfarin & Trimethoprim-Sulfamethoxazole Interaction

Trimethoprim-sulfamethoxazole (TMP-SMX, sold as Bactrim, Septra) is one of the most dangerous antibiotic interactions with warfarin, causing dramatic INR elevation and significantly increasing the risk of major and fatal hemorrhage ^[1]. The sulfamethoxazole component inhibits CYP2C9, the enzyme responsible for metabolizing the more potent S-enantiomer of warfarin, while trimethoprim may independently contribute to anticoagulant potentiation through inhibition of dihydrofolate reductase, impairing vitamin K-dependent clotting factor synthesis ^[2]. A population-based study found that co-dispensing TMP-SMX with warfarin was associated with a 4.6-fold increase in the risk of hospitalization for upper gastrointestinal bleeding compared to patients prescribed amoxicillin ^[1].

This interaction is among the most clinically consequential because TMP-SMX is frequently prescribed for common infections (urinary tract infections, skin infections) in outpatient settings, where INR may not be monitored immediately, and patients may not recognize the interaction risk ^[3]. Multiple fatalities have been attributed to TMP-SMX-warfarin interactions, often involving patients who did not have INR monitoring during the antibiotic course ^[1].

Warfarin exists as a racemic mixture of R-warfarin and S-warfarin. S-warfarin is 3-5 times more potent than R-warfarin and is metabolized primarily by cytochrome P450 2C9 (CYP2C9) ^[2]. Sulfamethoxazole is a moderate-to-strong inhibitor of CYP2C9, reducing the clearance of S-warfarin and causing disproportionate increases in anticoagulant activity ^[1]. Trimethoprim inhibits dihydrofolate reductase, which is involved in folate metabolism essential for DNA synthesis and cell division — this can independently impair the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) in the liver through folate depletion ^[2]. Additionally, trimethoprim can reduce vitamin K production by intestinal bacteria through its antibiotic effect on gut flora ^[3].

The combined effect of CYP2C9 inhibition (raising S-warfarin levels), dihydrofolate reductase inhibition (impairing clotting factor synthesis), and gut flora disruption (reducing vitamin K production) produces a triple-mechanism potentiation of warfarin's anticoagulant effect that is more pronounced than most single-mechanism drug interactions ^[1].

A landmark Canadian population-based study found that TMP-SMX co-prescription with warfarin was associated with a 4.6-fold increased risk of hospitalization for GI bleeding within 14 days ^[1]. Another study found that the mean INR increase was 2.7 units within 5-7 days of starting TMP-SMX, with some patients experiencing INR elevations above 10.0 ^[2]. A case series documented intracranial hemorrhage, massive gastrointestinal bleeding, and hematuria requiring transfusion in patients on warfarin who received standard courses of TMP-SMX ^[3]. The interaction can manifest within 3-5 days of starting TMP-SMX and may persist for 5-7 days after completion ^[1]. Patients who are CYP2C9 poor metabolizers have even greater risk, as their baseline S-warfarin clearance is already reduced ^[2]. This interaction is ranked by many clinical references as one of the top 10 most dangerous drug-drug interactions in clinical practice ^[3].

Avoid TMP-SMX in patients on warfarin whenever an alternative antibiotic is available ^[1]. For urinary tract infections, nitrofurantoin (Macrobid), cephalexin, or fosfomycin are alternatives without significant warfarin interaction ^[2]. For skin and soft tissue infections, cephalexin, clindamycin, or doxycycline can substitute for TMP-SMX ^[3]. If TMP-SMX is medically necessary, proactively reduce the warfarin dose by 25-50% when starting TMP-SMX ^[1]. Check INR at baseline, at days 3-5 after starting TMP-SMX, and twice weekly for the antibiotic duration ^[2]. After completing TMP-SMX, continue enhanced INR monitoring for 7-10 days as the interaction effect resolves ^[1]. Prescribe vitamin K (phytonadione) 1-2.5 mg orally if INR exceeds 5.0 without bleeding ^[3]. For INR >9.0 or active bleeding, manage per warfarin reversal protocols (IV vitamin K, PCC, FFP) ^[1].

Check INR before starting TMP-SMX, at days 3-5 (critical timepoint), then twice weekly during therapy ^[1]. Continue INR checks at 3-5 days and 7-10 days after TMP-SMX completion ^[2]. If INR exceeds the therapeutic range but remains below 5.0, reduce the warfarin dose and recheck in 2-3 days ^[1]. If INR exceeds 5.0, hold warfarin, consider oral vitamin K 1-2.5 mg, and recheck INR in 24 hours ^[3]. If INR exceeds 9.0 or bleeding develops, follow emergency warfarin reversal protocols ^[1]. Monitor hemoglobin and hematocrit if bleeding is suspected ^[2]. Educate patients about bleeding signs: blood in urine (red or cola-colored), blood in stool (bright red or black and tarry), unusual bruising, prolonged bleeding from cuts, nosebleeds lasting >10 minutes, sudden severe headache, abdominal pain, or any unexplained bleeding ^[3]. Ensure the anticoagulation clinic or managing provider is notified whenever TMP-SMX is prescribed ^[1].

For uncomplicated urinary tract infections, nitrofurantoin (Macrobid) is an excellent first-line alternative — it does not interact with warfarin and has good coverage for common uropathogens including many E. coli strains ^[2]. Fosfomycin (Monurol) is a single-dose oral option for uncomplicated cystitis in women without warfarin interaction ^[1]. Cephalexin (Keflex) provides broad coverage without CYP2C9 inhibition ^[3]. For skin and soft tissue infections (including MRSA coverage), doxycycline is effective and has minimal warfarin interaction (though INR should still be monitored) ^[2]. Clindamycin provides MRSA coverage without significant CYP-mediated warfarin interaction ^[3]. For Pneumocystis jirovecii prophylaxis in immunocompromised patients, dapsone or atovaquone are alternatives to TMP-SMX, though each has its own side effect profile ^[1]. Patients on warfarin who frequently require antibiotic therapy should be evaluated for transition to direct oral anticoagulants (apixaban, rivaroxaban) which have fewer antibiotic interactions ^[2].